Wiley Acquires SimBioSys

HOBOKEN, N.J.--()--John Wiley & Sons, Inc., a global provider of knowledge and knowledge-enabled solutions that improve outcomes in research, professional practice, and education, announced today that it has acquired SimBioSys Inc., a provider of scientific software tools that facilitate the drug discovery process. Terms were not disclosed.

SimBioSys is a pioneer in the field of computer-aided retrosynthetic analysis where it supports chemists in the challenges of organic synthesis. It was founded in 1996, privately held, and is based in Toronto, Canada.

“Wiley has deep roots in top quality chemistry publishing with high-profile international chemistry society partnerships and extensive chemical databases, journals, books and references,” said Steve Miron, Senior Vice President of Wiley’s Global Research business. “By combining our traditional published content and databases with machine learning algorithms, we can support chemists in innovative research as they advance world knowledge.”

“The acquisition of SimBioSys accelerates the development of Wiley Science Solutions, our integrated suite of workflow tools for researchers,” said Dr. Mike Davis, Vice President and Managing Director, Research Innovations “SymBioSys has developed technology that enables the computer to learn organic chemistry. These tools enable chemists working in industry and academia to find new and better ways of synthesizing target compounds, saving them time and money.”

The SimBioSys ARChem Route Designer is an expert system that helps chemists design viable synthetic routes for target molecules. ARChem’s knowledge of organic chemistry is automatically derived from reaction databases such as Wiley’s CIRX Reaction Database.

About Wiley

Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides print and digital content, and education solutions including online program management services for higher education institutions and course management tools for instructors and students.

About SimBioSys

SimBioSys is a recognized leader in the field of rational drug discovery software. Providing a wide range of software solutions, the company is focused on the development of scientific tools to facilitate the drug discovery process. It retains a constant focus on the innovation of algorithms to provide improved throughput and accuracy in the fields of flexible docking, virtual screening and de-novo structure design, and computer-aided retrosynthetic analysis. With attention to detail, ease-of-use, and improved productivity, SimBioSys has built a strong reputation of delivering state-of-the-art scientific solutions to biotechnology and pharmaceutical companies.

Contacts

John Wiley & Sons, Inc.
Investor Relations
Brian Campbell, 201-748-6874
bricampbel@Wiley.com
or
Press
Linda Dunbar, 201-748-6390
LDunbar@Wiley.com
or
Tom Griffin, +44 (0) 1865 476213
TGriffin@Wiley.com

Release Summary

Wiley announced today that it has acquired SimBioSys Inc., a provider of scientific software tools that facilitate the drug discovery process.

Contacts

John Wiley & Sons, Inc.
Investor Relations
Brian Campbell, 201-748-6874
bricampbel@Wiley.com
or
Press
Linda Dunbar, 201-748-6390
LDunbar@Wiley.com
or
Tom Griffin, +44 (0) 1865 476213
TGriffin@Wiley.com